Prognostic factors in patients with pancreatic cancer
- Authors:
- De-Xiang Zhang
- Yue-Di Dai
- Su-Xu Yuan
- Li Tao
-
View Affiliations
Affiliations: Department of General Surgery, Jinshan Hospital Affiliated to Fudan University, Shanghai 200540, P.R. China, Department of Medical Oncology, Cancer Hospital of Fudan University, Minhang Branch, Shanghai 200240, P.R. China, Department of Medical Oncology, the First Affiliated Hospital of Soochow University, Suzhou 215006, P.R. China
- Published online on: December 8, 2011 https://doi.org/10.3892/etm.2011.412
-
Pages:
423-432
Metrics:
Total
Views: 0 (Spandidos Publications: | PMC Statistics:
)
Metrics:
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics:
)
This article is mentioned in:
Abstract
The identification of prognostic factors for pancreatic cancer patients could provide insightful information for their management in the clinic. A total of 302 pancreatic cancer patients were enrolled in this study. The clinicopathological characteristics, treatment selection and laboratory test data were retrospectively retrieved from the medical records and follow‑up data were obtained via telephone interview. Cox survival analysis was used to assess the potential prognostic factors, and survival curves were obtained by Kaplan-Meier analyses. The mortality rate of the patients was 83.4% (252/302) and the median survival of these patients was 6.1 months, with 1-, 2- and 3-year survival rates of 30.1 (91/302), 10.6 (32/302) and 2.6% (8/302), respectively. The most influential factors for the survival of these patients were the site of primary cancer, tumor stage, treatment selection, serum levels of glutamic‑pyruvic transaminase, albumin, lactate dehydrogenase and hemoglobin, and white blood cell counts (P<0.05). The median survival of patients who did not receive any treatment or just received supportive treatment was 1.3 months, while the median overall survival of patients who underwent surgery, chemotherapy, biliary drainage therapy, arterial interventional chemotherapy and comprehensive treatment was 11.0, 7.3, 3.5, 9.0 and 11.0 months, respectively (P<0.05). Furthermore, single-drug chemotherapy was not statistically associated with patient survival in those who received the multi-drug regimen (P>0.05). However, the mortality risk of patients who received platinum chemotherapy was decreased [hazard ratio (HR)=0.56, 95% CI 0.35-0.88, P=0.011] compared to the patients who did not receive this treatment (P<0.05). Tumor stage, treatment selection, serum albumin levels, urea nitrogen, CA19-9, white blood cell and platelet counts were independent prognostic factors for the prediction of survival in pancreatic cancer. Future studies are required in order to verify these data. Chemotherapy with platinum regimens could improve overall survival in patients with pancreatic cancer.
View Figures |
Figure 1
|
 |
Figure 2
|
 |
Figure 3
|
 |
Figure 4
|
 |
Figure 5
|
 |
Figure 6
|
 |
Figure 7
|
View References
|
1.
|
D GoldsteinS CarrollM ApteModern
management of pancreatic carcinomaIntern Med
J34475481200410.1111/j.1444-0903.2004.00658.x15317546
|
|
2.
|
K HirataT SatoM MukaiyaResults of 1001
resections for invasive ductal adenocarcinoma of the pancreasArch
Surg132771776199710.1001/archsurg.1997.014303100850189230864
|
|
3.
|
A NakaoA HaradaT NonamiLymph node
metastasis in carcinoma of the body and tail of the pancreasBr J
Surg8410901092199710.1002/bjs.18008408139278647
|
|
4.
|
K ShimadaY SakamotoT SanoPrognostic
factors after distal pancreatectomy with extended lymphadenectomy
for invasive pancreatic adenocarcinoma of the body and
tailSurgery139288295200610.1016/j.surg.2005.08.00416546491
|
|
5.
|
JP NeoptolemosDD StockenH FriessA
randomized trial of chemoradiotherapy and chemotherapy after
resection of pancreatic cancerN Engl J
Med35012001210200410.1056/NEJMoa03229515028824
|
|
6.
|
QH ZhangQX LiClinical analysis of 2340
cases of pancreatic carcinomaNatl Med J
China84214218200415059537
|
|
7.
|
M KandaT FujiiY KoderaNutritional
predictors of postoperative outcome in pancreatic cancerBr J
Surg98268274201110.1002/bjs.730520960457
|
|
8.
|
Y MurakamiK UemuraT SudoNumber of
metastatic lymph nodes, but not lymph node ratio, is an independent
prognostic factor after resection of pancreatic carcinomaJ Am Coll
Surg211196204201010.1016/j.jamcollsurg.2010.03.03720670857
|
|
9.
|
U BoggiM del ChiaroC CrocePrognostic
implications of tumor invasion of adhesion to peripancreatic
vessels in resected pancreatic
cancerSurgery146869881200910.1016/j.surg.2009.04.02919744432
|
|
10.
|
J FatimaT SchnelldorferJ
BartonPancreatoduodenectomy for ductal adenocarcinoma: implications
of positive margin on survivalArch
Surg145167172201010.1001/archsurg.2009.28220157085
|
|
11.
|
V HeinemannPresent and future treatment of
pancreatic carcinomaSemin
Oncol292331200210.1053/sonc.2002.3426912094335
|
|
12.
|
YJ ChuaD CunninghamAdjuvant treatment for
respectable pancreatic cancerJ Clin
Oncol2345324537200510.1200/JCO.2005.17.95416002844
|
|
13.
|
D LiK XieR WolffPancreatic
cancerLancet36310491057200410.1016/S0140-6736(04)15841-8
|
|
14.
|
KP JooBY YongK Yong-TaeSurvival and
prognostic factors of unresectable pancreatic cancerJ Clin
Gastroenterol428691200810.1097/01.mcg.0000225657.30803.9d18097296
|
|
15.
|
V HeinemannGemcitabine in the treatment of
advanced pancreatic carcinoma: a comparative analysis of randomized
trialsSemin Oncol29916200210.1053/sonc.2002.3737212577228
|
|
16.
|
B EmilioM MicheleG AlainGemcitabine-based
combinations for inoperable pancreatic carcinoma: have we made real
progress? A meta-analysis of 20 phase 3
trialsCancer110525533200710.1002/cncr.2280917577216
|
|
17.
|
V HeinemannR LabiancaA HinkeIncreased
survival using platinum analog combined with gemcitabine as
compared to single-agent gemcitabine in advanced pancreatic cancer:
pooled analysis of two randomized trials, the GERCOR/GISCAD
intergroup study and a German multicenter studyAnn
Oncol1816521659200710.1093/annonc/mdm283
|
|
18.
|
HA Burris IIIMJ MooreMR GreenImprovements
in survival and clinical benefit with gemcitabine as first-line
therapy for patients with advanced pancreas cancer: a randomized
trialJ Clin Oncol152403241319979196156
|
|
19.
|
F TakeoN ToshioG NaotoEvaluation of the
prognostic factors and significance of lymph node status in
invasive ductal carcinoma of the body or tail of the
pancreasPancreas394854201010.1097/MPA.0b013e3181bd5cfa19910836
|
|
20.
|
W IchiroS SatoshiK MasaruOnset symptoms
and tumor locations as prognostic factors of pancreatic
carcinomaPancreas28160165200410.1097/00006676-200403000-0000715028948
|
|
21.
|
T FarukA FarukA SuleymanPrognostic factors
in pancreatic carcinoma serum LDH levels predict survival in
metastatic diseaseAm J Clin
Oncol24547550200110.1097/00000421-200112000-0000311801751
|
|
22.
|
J LouhimoH AlfthanUH StenmanSerum HCG beta
and CA72-4 are stronger prognostic factors than CEA, CA19-9 and
CA242 in pancreatic
cancerOncology66126131200410.1159/00007743815138364
|
|
23.
|
JE KimKT LeeJK LeeClinical usefulness of
carbohydrate antigen 19-9 as a screening test for pancreatic cancer
in an asymptomatic populationJ Gastroenterol
Hepatol19182186200410.1111/j.1440-1746.2004.03219.x14731128
|
